Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology , Irbid, Jordan.
Department of Pharmacy Practice, Faculty of Pharmacy, Zarqa University , Zarqa, Jordan.
Expert Rev Pharmacoecon Outcomes Res. 2021 Feb;21(1):93-104. doi: 10.1080/14737167.2020.1766969. Epub 2020 May 29.
: Pharmacoeconomics estimates the value of pharmaceutical products and services and provides healthcare decision-makers with valuable information. Pharmacoeconomic evaluations have not been found to be influential in the Jordanian health care system. Although pharmacoeconomics as a concept is becoming more recognized in the pharmaceutical world, there are still some barriers to its implementation. : To establish the perceived barriers to the implementation of pharmacoeconomics in Jordan. : A qualitative study with semi-structured interviews was conducted. Participants were chosen if they might benefit from the application of pharmacoeconomics; such as members of Pharmacy and Therapeutics Committees (PTCs) in public, private, and teaching hospitals; administrative pharmacists on drug pricing committees; those who produce pharmacoeconomic data such as academics; and administrative pharmacists in the Joint Procurement Department (JPD). The interviews were recorded and transcribed. Transcripts were analyzed using a thematic analysis approach. : Three main barriers to the implementation of pharmacoeconomics were identified. These were related to the nature of the decision-making process, the lack of pharmacoeconomic data, and inadequate knowledge about pharmacoeconomics. : The current use and impact of pharmacoeconomic evaluations in Jordanian healthcare decision-making is restricted, in part, due to the barriers outlined by the respondents.
药物经济学评估药品和服务的价值,并为医疗保健决策者提供有价值的信息。药物经济学评估在约旦的医疗保健系统中并没有发现有影响力。尽管药物经济学作为一个概念在制药领域越来越被认可,但在实施过程中仍然存在一些障碍。
确定在约旦实施药物经济学的感知障碍。
采用半结构式访谈的定性研究。如果参与者可能受益于药物经济学的应用,例如公共、私人和教学医院的药剂和治疗委员会(PTC)成员;药品定价委员会的行政药剂师;生产药物经济学数据的人,如学者;以及联合采购部(JPD)的行政药剂师,则选择他们参加。对访谈进行了记录和转录。使用主题分析方法对转录本进行了分析。
确定了实施药物经济学的三个主要障碍。这些障碍与决策过程的性质、缺乏药物经济学数据以及对药物经济学知识的不足有关。
约旦医疗保健决策中药物经济学评估的当前使用和影响受到限制,部分原因是受访者所概述的障碍。